Sensitive detection methods utilizing patient liquid biopsies have been used to track ESR1 somatic mutations during tumor progression and this approach (mutation tracking) has the potential to be used to guide sequential treatment options in patients, particularly if it can be applied to circulating tumor DNA (209). Here, ESR1 is linked to neoplasm.